Federal health authorities moved to reduce the number of routinely recommended childhood vaccines, shifting several shots to targeted or shared‑decision categories. The change—announced by HHS and the CDC—was framed as aligning U.S. guidance with peer nations but was implemented without the customary advisory‑committee process. BIO and other industry groups publicly warned the move risks undermining public trust and could affect vaccine uptake and R&D planning.